Background And Objectives: In clinical practice, some patients are diagnosed with diabetic nephropathy (DN) combined with acute tubulointerstitial nephritis (ATIN) through renal biopsy. There is relatively little research on the treatment and prognosis of such patients, and no consensus exists on the use of glucocorticoid for treatment. Therefore, our study explores the progression of DN combined with ATIN and the renal outcomes after treatment with glucocorticoid.
Methods: This study retrospectively analyzed patients diagnosed with DN combined with ATIN through renal biopsy at our center from January 1, 2015, to December 31, 2021. We collected general patient information, laboratory indicators, renal pathology indicators, and the glucocorticoid usage after kidney biopsy. Follow-up data were collected from medical records. Statistical analysis methods included t-tests, non-parametric tests, and chi-square tests. Univariate and multivariate Cox regression analyses were used to evaluate the risk factors for renal endpoint events in patients. Statistical significance was defined as -values < 0.05.
Results: In this study, a total of 67 patients were included. The subjects were divided into two groups based on whether they received glucocorticoid treatment: 33 patients in the steroid group and 34 in the non-steroid group. In the steroid group, 19 patients reached the renal endpoint event, which was significantly higher than in the non-steroid group (57.58% vs. 29.41%, = 0.038). Univariate Cox regression analysis showed that serum creatinine (HR = 1.008, < 0.001), albumin (HR = 0.919, < 0.001), 24-h urinary protein (HR = 1.093, = 0.002), hemoglobin (HR = 0.964, = 0.001), triglycerides (HR = 1.12, = 0.04), and the use of glucocorticoid (HR = 2.507, = 0.019) were influencing factors for renal endpoint events in patients with DN combined with ATIN. Multivariate Cox regression analysis showed that albumin (HR = 0.863, = 0.003) was an independent risk factor for renal endpoint events in patients with DN combined with ATIN.
Conclusions: The use of glucocorticoid in treatment does not improve renal prognosis in patients with DN combined with ATIN. Lower levels of albumin are associated with a worse renal prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259057 | PMC |
| http://dx.doi.org/10.1080/0886022X.2024.2379002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Lung cancer ranks among the foremost causes of mortality associated with cancer. Ensartinib is a highly effective oral anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive lung adenocarcinoma. This report presents a case of acute renal failure attributed to the administration of ensartinib.
View Article and Find Full Text PDFA Case of Autoimmune Hemolytic Anemia Following COVID-19 Infection Accompanied by Acute Tubulointerstitial Nephritis in a Kidney Transplant Recipient.
Transplant Proc
December 2024
Department of Surgery, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Republic of Korea. Electronic address:
Background: Acute tubular injury is one of the main causes of acute tubular injury (acute kidney injury ) in patients with COVID-19 infection. Autoimmune hemolytic anemia (AIHA) is also one of the autoimmune complications of COVID-19. However, AIHA accompanied by acute tubulointerstitial nephritis (ATIN) caused by SARS-CoV-2 is rarely reported.
View Article and Find Full Text PDFSacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis.
BMC Nephrol
November 2024
Department of Medicine, Division of Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Background: Sacituzumab govitecan is an antibody-drug conjugate that is FDA approved for refractory metastatic triple-negative breast cancer. It targets the human trophoblastic cell-surface antigen 2 (Trop-2) with SN-38, a topoisomerase I inhibitor, attached to the antibody [1]. SN-38 breaks DNA strands and induces tumor apoptosis [2].
View Article and Find Full Text PDFAcute tubulointerstitial nephritis associated with infliximab therapy in a patient with Crohn's disease: a case report.
CEN Case Rep
November 2024
Internal Medicine Department, Security Forces Hospital Program, Riyadh, Saudi Arabia.
We report the case of a 39-year-old man who presented with a history of generalized fatigue, nausea, subjective fever with rigors, and renal dysfunction after receiving infliximab (IFX) therapy for Crohn's disease. A renal biopsy revealed acute tubulointerstitial nephritis (ATIN). After other causes of acute kidney injury were excluded, steroid therapy was initiated, his fever subsided, and kidney function improved.
View Article and Find Full Text PDFNLRP3 inflammasome activation and macrophage distribution in kidney tissues from patients with acute oxalate nephropathy.
Kidney Res Clin Pract
September 2024
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Article Synopsis
- The study examined the activation of the NLRP3 inflammasome pathway and macrophage distribution in patients with acute oxalate nephropathy (AON) compared to acute tubulointerstitial nephritis (ATIN).
- In AON patients, significant increases in inflammation and NLRP3-related markers were observed, along with a notable presence of oxalate deposits and more severe tissue damage compared to ATIN patients.
- A lower ratio of M1 to M2 macrophages was linked to worse kidney function and chronic lesions, suggesting the need for further research on these macrophage dynamics in kidney injury.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!